Monday Market Upgrades and Downgrades

In Barry Absence 
I have am giveing the most obvious 
$Clny  news

Rafarma to Commence Production in Thailand; Predicted to Be The Region’s “Cannabis Capital”

Ljubljana, Slovenia, Aug. 23, 2019 (GLOBE NEWSWIRE) — RAFARMA PHARMACEUTICALS INC. “OTC:(RAFA) – Rafarma is positioning to expand its operations in the “next big thing” in cannabis production—Thailand.

Rafarma is currently in talks with Thai partners to open cannabis farms and specialized cannabis spa and detox centers in Thailand. Projected plans are to construct hemp growing greenhouses as well as a specialized spa/detox center with full-control patient living facilities the following year on approximately 1000 rai (160 hectares) in the Ranong province of Thailand.

“The forecast for the legal cannabis market in Asia is rosy—it’s expected to swell to $8.5 billion by 2024 from practically nothing today. One of the main questions surrounding this potential market is which country will establish an early lead as a supplier. Surprisingly, Thailand has a good shot” according to Bloomberg Businessweek (

Despite its history of tough drug laws, Thailand is looking to become the region’s cannabis capital. On February 20, 2019 Thailand passed an amendment to its current drug laws legalizing marijuana production for agricultural, commercial, medical and industrial purposes. The Bloomberg article goes on to report that in addition to changes in the laws, a key member of the current government coalition is pushing for full legalization of Thailand’s marijuana market, projected to grow to $661 million within five years, according to cannabis industry researchers.

Based on the legal changes, the Thailand Ministry of Health has undertaken several steps allowing storage of cannabis for medical and research purposes. Also, possession of cannabis is allowed for government organizations, private universities, private enterprises, farms, and for international logistics carriers and patients. Thailand is currently one of the first countries in the world that is expected to further relax laws to allow recreational cannabis use in the near future. 

Already, under current laws, scientists that practice traditional Thai medicine (the Spa Industry), as well as doctors, the Red Cross and farms that receive the permission from the government, are allowed to store and sell cannabis. The Thailand Ministry of Health officially recognized the properties of cannabis for wound healing, pain analgesia, after-illness or surgery rehabilitation, expectoration, cholagogue, anti-cancer, anti-stress, anti-depression and anti-insomnia.

As Thailand already offers the opportunity of combining the production of cannabis with its use and sales in unique specialized SPA centers and detox centers, and as such applications fully comply with current legislation, Rafarma is poised to meet the demand.

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company’s filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For more information contact:

(307) 429-2029

Predictive Technology Group, Inc. (OTC PINK: PRED),

SALT LAKE CITY, Aug. 23, 2019 (GLOBE NEWSWIRE) — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces the appointment of Jeff Acuff to the newly created position of Chief Commercial Officer of its wholly owned subsidiary Predictive Biotech.

Mr. Acuff will be responsible for the commercial strategy of Predictive Biotech’s existing human cell and tissue product (HCT/P) business, and will implement programs and business development strategies aimed at driving sales and increasing physician awareness of HCT/P treatment options. He also will lead the commercial development of new product candidates, and the expansion and use of the human cell and tissue products into new vertical-market targets that include wound management and aesthetics. Additionally, he will oversee the long-term business development strategy for cellular therapies being developed by Predictive Therapeutics.

“Jeff brings a deep knowledge of the healthcare industry, a clear focus of physician and patient needs, and a proven track record of successful execution in ortho-biologic sales, which makes him ideally suited to lead the commercial efforts for Predictive Biotech, as well as the development of the Company’s sales expansion plans,” said Mr. Eric Olson, CEO of Predictive Biotech. “Under his leadership, I am confident we will continue to build upon the Company’s solid foundation in sales and strengthen our ability to bring quality products to our physician customers.”

“I am very excited and honored to lead such a talented and proven team as we continue to focus on building the Company’s portfolio and capabilities for the future,” said Mr. Acuff. “Predictive Biotech has made the safety, efficacy and quality of its human cell and tissue products the number one priority in serving physician customers and their patients. The Company has delivered over 95,000 allografts to date and is proud to serve as a reliable, quality manufacturer. I look forward to building upon these trusted customer relationships to best serve patient needs.”

Mr. Acuff has more than 25 years of commercial and leadership experience concentrated in the medical device and biologics industry, and has a proven track record for building high-performing teams and achieving exceptional results. He most recently served as the Commercial Excellence Leader for GE Healthcare. Prior to joining GE Healthcare, Mr. Acuff was Senior Vice President of Sales leading the commercial efforts of Bioventus, a private equity-owned ortho-biologics company, and was Vice President of Sales, Americas for Varian Medical Systems, where he helped develop and lead the commercial strategy and implementation for its radiation oncology business. Before that, he served for 13 years at Medtronic in various roles, including Vice President of Sales, Biologics and Vice President of Enabling Technologies Sales & Marketing. During his tenure at Medtronic, he led sales organizations in both mature and fast-growing market segments including interventional cardiology, interventional radiology, endovascular surgery, spine, and biologics.

Mr. Acuff holds a Bachelor of Business Administration in Management from the University of Memphis and completed an Executive Program at the Kellogg School of Management at Northwestern University.

About Predictive Biotech, Inc.
Predictive Biotech, Inc., a Salt Lake City-based life sciences company formed in 2015, is a leader in human cell and tissue products for use in cellular therapies and regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive’s four main placental-derived and Wharton’s Jelly umbilical cord-derived products. Predictive Biotech’s current products are regulated by the FDA under 21 CFR part 1271 section 361 as minimally manipulated allografts intended for homologous use.

About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at,,, and

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

For more information, visit or contact Investor Relations:

Investor Contact
LHA Investor Relations
Jody Cain
Kevin Mc Cabe

ENDO – update

Predictive Launches PGxPLUS+ Test for Patients with Chronic Pain of Endometriosis and Other Illnesses


has begun to commercialize PGxPLUS+, a test developed to assess the effect of genetic factors in the way a patient responds to pain medications, for people living with endometriosisosteoarthritislumbar disc disease, and other medical conditions associated with chronic pain.

According to Predictive Laboratories, statistics indicate that more than 90% of individuals worldwide carry genetic variants that affect the way their bodies react to certain medications. This means that two patients taking similar doses of the same medication may actually have up to 1,000-fold difference in the levels of the drug circulating in their blood, because their bodies process the medication differently.

The PGxPLUS+ test panel is one of the most thorough pharmacogenetic tests currently available on the market, the company said. (Pharmacogenomics is the field that studies how genetic factors may affect the safety and effectiveness of a drug.)

PGxPLUS+ is able to predict the effects of 112 genetic variants from 38 genes on the body’s ability to metabolize more than 150 medications, which also include drugs for pain management.

In the patients’ personalized test results, each type of medication (e.g., muscle relaxants, pain management), may fall into three different categories: standard precautions; use with caution; and consider alternatives. Based on these findings, physicians may then select the best course of treatment for each patient.

“The PGxPLUS+ pharmacogenetic test has been very helpful in my day-to-day practice.  The results give insights into why some patients are not responding to medications as expected.  With the help of these test results, I have been able to start or switch medications for patients more successfully.  The PGxPLUS+ test helps me avoid prescribing medications that a patient won’t metabolize well, leading to better and more personalized patient care,” Bryt Christensen, MD, a pain specialist, said in a press release.

In addition, the company announced it has achieved a milestone of enrolling 350 patients into a U.S. Food and Drug Administration Investigational Review Board (IRB)-approved clinical trial designed to explore the mechanisms underlying chronic pain and to evaluate participants’ response to different types of pain medications.

The trial is enrolling patients with chronic pain who are taking high doses of opioids (more than 50 morphine milligram equivalents, or MMEs, per day). The main goal of the study is to analyze patients’ genetic backgrounds to look for genetic variants that may be involved in their responses to opioids, pain thresholds, and the chances of becoming addicted to opioids.

“The ability to effectively treat individuals in pain represents a significant market opportunity and of even greater importance it serves an obligation of society to alleviate the current pain and suffering of an individual in a safer and more effective manner,” said Bradley Robinson, CEO of the Predictive Technology Group.

“Our Company is both identifying the most effective ways to treat pain at a personalized level and working to understand the underlying cause of diseases like osteoarthritis, lumbar disc disease and endometriosis to treat or prevent the root cause of the pain. We are pleased to add the PGxPLUS+ test to our portfolio of regenerative medicine and diagnostic products focused on treating chronic pain diseases,” Robinson said.

Predictive Laboratories is a wholly owned subsidiary of the Predictive Technology Group, a life sciences company dedicated to the the use of data analytics for disease identification and clinical intervention through innovative gene-based therapies.

The company already has developed and licensed several prognostic DNA tests and new forms of therapy for different medical conditions associated with chronic pain. This is part of a continuing effort to minimize the use of opioids, which have been shown to be either ineffective or have severe side effects on a third of patients who take them regularly to control chronic pain

PRED EV close of 2019 between $25 to $30 

PRED EV close of 2019 between $25 to $30 

We see PRED at $28 based on our valuation of similar companies with a multiple of therapeutics in pre-FDA IND status. This is not back of the envelope but a detailed evaluation of PRED’s announced portfolio of diagnostics, its announced global collaborations, and new IRB approved therapeutics. 

PRED’s a bit harder to value because not only do they supply over 1,100+ clinics with regenerative tissue products, they have a growing portfolio of synergistic diagnostic-therapeutic-new IP in development. They keep announcing details and then the announcement is followed-up with the staffing to execute. 

Then there is the IP within Dr. Ward’s published research papers that will be presented at ASRM in September. We know something about this technology and space as we have a Nobel in Medicine and other world-class researchers within our companies that are non-related to PRED. Anyone who says PRED does not have science is blind or one of the SHORT FRAUDSTERS like LL. 

The other unknown but obviously ongoing is other companies are coming to PRED to collaborate with FDA Phase 1 and 2 and 2b therapeutics. They come to PRED because of its Board and PRED having resources to invest – my insight is PRED can dial 911 for significant cash at will. Many lose sight that John Sorenteno was COO of Pfizer and running $34 to $38 billion of Pfizer business unit(s). Why would other therapeutic technologies come to PRED? Simple because their law firm is WSGR, the world’s leading life science law firm which I have posted comments about on this blog. WSGR is also one of the greatest match-markers in the history of any law firm, they incorporated Google, Sysco, Oracle, eBay, and a zillion other name brand tech and life science companies. I personally know Mario Rosati (WSGR founder) and I assure if any number of Hindenburg’s report was right, WSGR would not represent PRED – no way in hell would they. Why would WSGR allow one of its attorneys to sit on PRED’s Advisory Board and open itself up to litigation – they would not. Logic also dictates that NASDAQ would not have met with PRED’s CEO for three hours nor showed PRED and group around its building and specifically taken Bradley Robinson to see where newly listed companies Ring the Bell. I was there and took those pictures. I think that was positive and we feel the story will soon be told. 

We are holding and will take some of our equity off the table at $25 to $30 per share and we have substantially more shares than most on this blog. 

I spoke with someone very famous yesterday and today, they are shareholders in PRED and are making a public statement, as soon as tomorrow that will discredit Hindenburg and the SHORTs on this and other blogs.


SPX/MKT note / FXI observations coming into next week 8.18.19

So sure, I’m constructive on the MKT to the extent that I don’t think we’re going into a bear MKT- and I DO think the “Daily” trend is likely to stay intact above 2820-40- on a closing basis.

I DO think, however- we will likely “churn” a bit within this trading range we have established between 2950-2840- this week into 8.23.19 when bigger signals start to fire and the TIME signal schematic begins to improve.

I’m hoping that we can maintain the current trend structure within the range highlighted above(2840-2950)-

We need to get through Tues-Thurs…

*I’m worried about FXI MKT– this week…This thing looks like its set up to move aggressively lower-  BUT, I thought that in late June and it never happened…

Here is the weekly chart- does NOT look good and we have SELL signals in weekly’s and dailies coming in this week…

Adam Lorraine-


The process of listing on NYSC or NASDAQ is a serious undertaking

Nasdaq has a fiduciary obligation to its traded companies and all those shareholders. The process of listing on NYSC or NASDAQ is a serious undertaking. 

While I appreciate your pain and frustration, NASDAQ has to get it right, and must complete their internal review of any applicant submission (Form 10), and gather any and all information necessary to comply with the listing regulations, not to mention FINRA and SEC laws and disclosures. 

Surely NASDAQ has requested clarification (it is mandated in the listing due-diligence process, which is linked below) to review and gather responses from Predictive and other sources to the Hindenburg report. What I did learn is Hindenburg is known to NASDAQ and not in a favorable or positive light. 

My insight tells me that review is near completion but certainly no NASDAQ official would have been allowed to reveal those details, in fact, the compliance team can not meet with Predictive but other officials can and have. Those meetings were not negative is all I can say. 

One logical observation, why would Bradly Robinson take a company, alleged to be ripe with misrepresentations and bad deeds, to become listed on a much stricter exchange? Why go through the millions of dollars and months and months of human resources, assemble a world-class Board and management team, invest days and nights over 15 months of hard work, all to file false and misleading statements (BTW statements that are audited and reviewed by law firm after law firm, auditors, and highly reputable wall street firms) with the aim to try and get away with a fabrication? It’s not logical. Do you know why? Because none of the allegations are accurate but for the manipulation of the market and profit. 

That’s my take for the moment, hope it helps you to hold and continue to be a shareholder.   


Whenever I invest in a company I look at the fundamentals but also like to see where the rubber meets the road.This morning at 10 am I had an appointment with with a quality Medical group using Predictives Corecyte.I have a sports hernia and have seen many doctors,chiropractors etc over the past four years with no relief, cortisone injections,PT, alternative medicine with no relief- so I decided that I am going to try PRED’s product first hand to see if it really works. I asked the nurse and practitioners some questions this morning: 

1. How long have you been using PRED’s Corecyte: For about 1 year and we found it far superior to the product we were using Amniotech for the past 4 years- we have had great results with Corecyte about 95% satisfaction of our patients. She said the key factor is PRED’s product is far superior with 1.1 Million live mesenchymal stem cells per ml-a much higher concentration than Amniotech.A higher concentration of stem cells reduces patients costs and administering multiple times- and real key much more effective. They also mentioned the professionalism of the company – they keep a live nitrogen freezer at there site. They have treated backs,necks,knees, shoulders with excellent results. Next week I have a follow up meeting so I will probably get my first injection- so I will keep everyone posted as I have thousands of reasons why. First impression where rubber meets the road : A ++ on quality of product and efficacy-company professionalism.